- Home
- CAC vs AUTL Comparison
CAC vs AUTL Comparison
Compare CAC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAC | AUTL |
|---|---|---|
| Founded | 1875 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.2M | 596.2M |
| IPO Year | 1996 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CAC | AUTL |
|---|---|---|
| Price | $57.29 | $1.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $47.00 | $8.50 |
| AVG Volume (30 Days) | 76.7K | ★ 1.6M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 6.08 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $41,739,000.00 | $10,120,000.00 |
| Revenue This Year | $19.15 | $80.32 |
| Revenue Next Year | $6.05 | $53.96 |
| P/E Ratio | $21.77 | ★ N/A |
| Revenue Growth | 16.96 | ★ 496.00 |
| 52 Week Low | $35.00 | $1.18 |
| 52 Week High | $60.59 | $2.58 |
Technical Indicators
Market Signals| Indicator | CAC | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 41.51 |
| Support Level | $56.91 | $1.37 |
| Resistance Level | $59.67 | $1.92 |
| Average True Range (ATR) | 1.89 | 0.09 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 60.53 | 13.76 |
Price Performance
Historical ComparisonAbout CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.